A review of the current status of G6PD deficiency testing to guide radical cure treatment for vivax malaria
Plasmodium vivax malaria continues to cause a significant burden of disease in the Asia-Pacific, the Horn of Africa, and the Americas. In addition to schizontocidal treatment, the 8-aminoquinoline drugs are crucial for the complete removal of the parasite from the human host (radical cure). While we...
| Auteurs principaux: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Langue: | English |
| Publié: |
MDPI
2023
|